Fusion Pharmaceuticals

Fusion Pharmaceuticals in its US$20 million commitment by the Canada Pension Plan Investment Board

Client

Fusion Pharmaceuticals

Value

US$20 million

Service

Emerging and High Growth Companies

Date Closed

Industry

Venture Capital

Lead Office

Toronto


 

On January 13, 2020, Fusion Pharmaceuticals announced it has received a commitment of up to US$20 million from the Canada Pension Plan Investment Board. The funding will be used to invest in new partnerships to expand the use of its platform which can create novel cancer treatments. The financing will also be used to target molecules that could lead to new treatments and be put towards the company’s lead clinical candidate, which is currently in a Phase 1 trial for treating solid tumors.

Fusion Pharmaceuticals is a growth stage firm specializing in biopharmaceutical precision oncology. Fusion Pharmaceuticals is focused on creating a safer and more effective form of radiation therapy by developing targeted alpha therapeutics.

The Canada Pension Plan Investment Board is an investment management organization specialized in making investments on behalf of Canadian contributors and beneficiaries, and holds investments in private equity, public equity, and real estate in 52 countries.

Osler, Hoskin & Harcourt LLP advised Fusion Pharmaceuticals with a team consisting of Chad Bayne, Michael Grantmyre and Sahil Chopra (Emerging and High Growth Companies).


Team
Chad Bayne
Key Contact

Chad Bayne

Partner, Emerging and High Growth Companies

Michael Grantmyre

Michael Grantmyre

Associate, Emerging and High Growth Companies

Sahil Chopra

Sahil Chopra

Associate, Emerging and High Growth Companies